MSD Manual

Please confirm that you are a health care professional

Loading

Gastrinoma

(Zollinger-Ellison Syndrome; Z-E Syndrome)

By

Minhhuyen Nguyen

, MD, Fox Chase Cancer Center, Temple University

Last full review/revision Jun 2019| Content last modified Jun 2019
Click here for Patient Education

A gastrinoma is a gastrin-producing tumor usually located in the pancreas or the duodenal wall. Gastric acid hypersecretion and aggressive, refractory peptic ulceration result (Zollinger-Ellison syndrome). Diagnosis is by measuring serum gastrin levels. Treatment is proton pump inhibitors and surgical removal.

Gastrinomas are a type of pancreatic endocrine tumor that arises from islet cells but can also arise from the gastrin-producing cells in duodenum and, much less rarely, other sites in the body. Gastrinomas occur in the pancreas or duodenal wall 80 to 90% of the time. The remainder occur in the splenic hilum, mesentery, stomach, lymph node, or ovary. About 50% of patients have multiple tumors. Gastrinomas usually are small (< 1 cm in diameter) and grow slowly. About 50% are malignant. About 40 to 60% of patients with gastrinoma have multiple endocrine neoplasia.

Symptoms and Signs

Zollinger-Ellison syndrome typically manifests as aggressive peptic ulcer disease, with ulcers occurring in atypical locations (up to 25% are located distal to the duodenal bulb). However, as many as 25% of patients do not have an ulcer at diagnosis. Typical ulcer symptoms and complications (eg, perforation, bleeding, obstruction) can occur. Diarrhea is the initial symptom in 25 to 40% of patients.

Diagnosis

  • Serum gastrin level

  • CT, scintigraphy, or positron emission tomography (PET) to localize

Gastrinoma is suspected by history, particularly when symptoms are refractory to standard acid suppressant therapy.

Serum gastrin level is the most reliable test. All patients have levels > 150 pg/mL (> 72.15 pmol/L); markedly elevated levels of > 1000 pg/mL (> 480 pmol/L) in a patient with compatible clinical features and gastric acid hypersecretion of > 15 mEq/hour establish the diagnosis. However, moderate hypergastrinemia can occur with hypochlorhydric states (eg, pernicious anemia, chronic gastritis, use of proton pump inhibitors), in renal insufficiency with decreased clearance of gastrins, in massive intestinal resection, and in pheochromocytoma.

A secretin provocative test may be useful in patients with gastrin levels  < 1000 pg/mL (< 480 pmol/L). An IV bolus of secretin 2 mcg/kg is given with serial measurements of serum gastrin (10 minutes and 1 minute before, and 2, 5, 10, 15, 20, and 30 minutes after injection). The characteristic response in gastrinoma is an increase in gastrin levels, the opposite of what occurs in patients with antral G-cell hyperplasia or typical peptic ulcer disease. Patients also should be evaluated for Helicobacter pylori infection, which commonly results in peptic ulceration and moderate excess gastrin secretion.

Once the diagnosis of gastrinoma has been established, the tumor or tumors must be localized. The first test is abdominal CT or somatostatin receptor scintigraphy, which may identify the primary tumor and metastatic disease. PET or selective arteriography with magnification and subtraction is also helpful. If no signs of metastases are present and the primary is uncertain, endoscopic ultrasonography should be done. Selective arterial secretin injection is an alternative.

Prognosis

Five- and 10-year survival are > 90% when an isolated tumor is removed surgically vs 43% at 5 years and 25% at 10 years with incomplete removal.

Treatment

  • Acid suppression

  • Surgical resection for localized disease

  • Chemotherapy for metastatic disease

Acid suppression

Proton pump inhibitors are the drugs of choice (eg, omeprazole or esomeprazole 40 mg orally 2 times a day). The dose may be decreased gradually once symptoms resolve and acid output declines. A maintenance dose is needed; patients need to take these drugs indefinitely unless they undergo surgery.

Octreotide injections, 100 to 500 mcg subcutaneously twice a day to 3 times a day, may also decrease gastric acid production and may be palliative in patients not responding well to proton pump inhibitors. A long-acting form of octreotide (20 to 30 mg IM once a month) can be used.

Surgery

Surgical removal should be attempted in patients without apparent metastases. At surgery, duodenotomy and intraoperative endoscopic transillumination or ultrasonography help localize tumors. Surgical cure is possible in 20% of patients if the gastrinoma is not part of a multiple endocrine neoplasia syndrome.

Chemotherapy

In patients with metastatic disease, streptozocin in combination with 5-fluorouracil or doxorubicin is the preferred chemotherapy for islet cell tumors. It may reduce tumor mass (in 50 to 60%) and serum gastrin levels and is a useful adjunct to omeprazole. Newer chemotherapies under investigation for insulinoma include temozolomide-based regimens, everolimus, or sunitinib. Patients with metastatic disease are not cured by chemotherapy.

Key Points

  • Most gastrinomas manifest with peptic ulcer symptoms, but some patients present with diarrhea.

  • About half of patients have multiple gastrinomas and about half have multiple endocrine neoplasia syndrome; half of gastrinomas are malignant.

  • Serum gastrin levels are usually diagnostic, but patients with borderline elevated levels may need a secretin provocative test.

  • Tumors can usually be localized with CT, somatostatin receptor scintigraphy, or positron emission tomography (PET).

  • Acid secretion is suppressed with a proton pump inhibitor, sometimes also with octreotide, pending surgical removal.

Click here for Patient Education
NOTE: This is the Professional Version. CONSUMERS: Click here for the Consumer Version
Professionals also read

Also of Interest

Videos

View All
Overview of Celiac Disease
Video
Overview of Celiac Disease
3D Models
View All
Mesenteric Ischemia–Intestinal Blood Supply
3D Model
Mesenteric Ischemia–Intestinal Blood Supply

SOCIAL MEDIA

TOP